Close Menu

Alacris Theranostics

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

Researchers plan to develop a device that supports nucleic acid sequencing and protein sequencing using plasmonic nanostructures.

Alacris' ModCell approach matches patients with appropriate therapies. 

NEW YORK (GenomeWeb News) – Alacris Theranostics today said that is has gained Illumina CSPro certification for next-generation sequencing.

NEW YORK (GenomeWeb News) – German firm Alacris Theranostics today announced a deal with GlaxoSmithKline for the application of Alacris' Modcell System for drug stratification.

ModCell uses a patient's normal genomic data as well as the genomic and transcriptomic profiles of the patient's tumor to generate object-oriented models that can be used to personalize cancer treatments.

Alacris Theranostics is using whole-genome sequence analysis to develop individualized cancer therapies while EyeSense is developing ophthalmic diagnostic systems for glucose monitoring of diabetes patients.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.